[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597923":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":33,"locations":40,"responsibleParty":60,"collaborators":18,"id":63,"slug":18,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":18,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":18,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: Cryocompression + Standard of Care Taxane-Based Chemotherapy","EXPERIMENTAL","Participants will be randomized and stratified by chemotherapy regimen and will complete:\n\n* Baseline visit with questionnaires\n* Standard of care chemotherapy visits with cryocompression\n* End of treatment visit",[13],"Device: Paxman Limb Cryocompression System",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm B: Standard of Care Taxane-based Chemotherapy","NO_INTERVENTION","Participants will be randomized and stratified by chemotherapy regimen and will complete:\n\n* Baseline visit with questionnaires\n* Standard of care chemotherapy visits\n* End of treatment visit",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Paxman Limb Cryocompression System","An investigational device designed to provide controlled cooling and compression to participant limbs during chemotherapy administration. The device is comprised of a control unit, connecting hose, and two limb wraps. The customizable limb wraps delivers continuous-flow cooling-and-compression to participant extremities",[9],[26],"PLCS",[28,31],{"name":29,"affiliation":5,"role":30},"Theresa Jabaley Leonarczyk, PhD, RN","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":5,"role":30},"Leonarczyk",[34,38],{"name":29,"role":35,"phone":36,"phoneExt":18,"email":37},"CONTACT","617-582-8037","theresa_jabaley@dfci.harvard.edu",{"name":39,"role":35,"phone":36,"phoneExt":18,"email":37},"Jabaley Leonarczyk, PhD, RN",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Boston","Massachusetts","02215","United States",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,57,59],{"name":55,"role":35,"phone":36,"phoneExt":18,"email":56},"Theresa Leonarczyk, PhD, RN","Theresa_jabaley@dfci.harvard.edu",{"name":58,"role":35,"phone":36,"phoneExt":18,"email":37},"Theresa Leonarczyk, PhD",{"name":29,"role":30,"phone":18,"phoneExt":18,"email":18},{"type":30,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Theresa Jabaley, PhD","Principal Investigator","100597923",false,"NCT07064798","Cryocompression for CIPN","Evaluating the Use of Limb Cryocompression to Reduce Taxane-induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults \\> 18 years of age\n* Gynecologic or breast malignancy\n* Starting 1st cycle of treatment with chemotherapy regimens:\n\n  * Weekly paclitaxel x 12 or weekly paclitaxel\u002Fcarboplatin x 12, Q2 weeks paclitaxel X4 (preceded by doxorubicin\u002Fcyclophosphamide). (Breast Oncology)\n  * Q3 weeks paclitaxel\u002Fcarboplatin X 6-8 (GYN)\n* Receiving treatment on the main campus of DFCI (these patients are currently seen on Yawkey 9 and 10 and at Chestnut Hill)\n* Able to complete questionnaires in English or Spanish\n\nExclusion Criteria:\n\n* Previous exposure to neurotoxic chemotherapy\n* Pre-existing neuropathy\n* History of Raynaud's phenomenon, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, post-traumatic cold dystrophy, peripheral arterial ischemia, or sickle cell disease\n* Undergoing desensitization\n* Lymphedema in the limb where the device would be applied\n* Open skin wounds or ulcers of the limbs where the device would be applied","ALL","18 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study aims to evaluate the effectiveness, tolerability, and safety of using cooling therapy and pressure (cryocompression) to reduce peripheral neuropathy, a condition affecting the nerves supplying the arms and legs (limbs) resulting in possible numbness, pain, and\u002For loss of motor function, that may occur as a result of taxane-based chemotherapy.\n\nThe name of the device used in this research study is:\n\n-Paxman Limb Cryocompression System (PLCS)",[79,80,81],"Chemotherapy-induced Peripheral Neuropathy","Taxane-Induced Peripheral Neuropathy","CIPN - Chemotherapy-Induced Peripheral Neuropathy",[83,79,80,84],"Peripheral Neuropathy","CIPN","2026-04-14",{"date":87,"type":88},"2026-04-15","ACTUAL",{"date":90,"type":88},"2025-10-22",{"date":92,"type":73},"2027-08",{"name":5,"class":6},1]